Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis
Annals of Hematology · 21.11.2026
DOI: 10.1007/s00277-026-07369-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 21.11.2026. Verfasst von Isabel García-Cabrera und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
García-Cabrera, I., Clavero, E., Alcalá, M., García-Sánchez, R., Casanova, M., Galán, M. C., Álvarez, M. A., Garzón, S., Fe, R., & Jiménez, M. (2026). Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis. Annals of Hematology. https://doi.org/10.1007/s00277-026-07369-3
Vancouver
García-Cabrera I, Clavero E, Alcalá M, García-Sánchez R, Casanova M, Galán MC, et al. Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis. Annals of Hematology. 2026. doi:10.1007/s00277-026-07369-3
BibTeX
@article{GarcaCabrera2026,
author = {García-Cabrera, Isabel and Clavero, Esther and Alcalá, Magdalena and García-Sánchez, Ricarda and Casanova, María and Galán, Maria C. and Álvarez, Miguel A. and Garzón, Sebastián and Fe, Rocío and Jiménez, María},
title = {Isa-Kd in relapsed/refractory multiple myeloma (RRMM): beyond controlled clinical trials – a detailed real-world analysis},
journal = {Annals of Hematology},
year = {2026},
doi = {10.1007/s00277-026-07369-3}
}
EUVIMED